Scientific advances in thoracic oncology 2016 Journal Article

  


Authors: Soo, R. A.; Stone, E. C. A.; Cummings, K. M.; Jett, J. R.; Field, J. K.; Groen, H. J. M.; Mulshine, J. L.; Yatabe, Y.; Bubendorf, L.; Dacic, S.; Rami-Porta, R.; Detterbeck, F. C.; Lim, E.; Asamura, H.; Donington, J.; Wakelee, H. A.; Wu, Y. L.; Higgins, K.; Senan, S.; Solomon, B.; Kim, D. W.; Johnson, M.; Yang, J. C. H.; Sequist, L. V.; Shaw, A. T.; Ahn, M. J.; Costa, D. B.; Patel, J. D.; Horn, L.; Gettinger, S.; Peters, S.; Wynes, M. W.; Faivre-Finn, C.; Rudin, C. M.; Tsao, A.; Baas, P.; Kelly, R. J.; Leighl, N. B.; Scagliotti, G. V.; Gandara, D. R.; Hirsch, F. R.; Spigel, D. R.
Article Title: Scientific advances in thoracic oncology 2016
Abstract: Lung cancer care is rapidly changing with advances in genomic testing, the development of next-generation targeted kinase inhibitors, and the continued broad study of immunotherapy in new settings and potential combinations. The International Association for the Study of Lung Cancer and the Journal of Thoracic Oncology publish this annual update to help readers keep pace with these important developments. Experts in thoracic cancer and care provide focused updates across multiple areas, including prevention and early detection, molecular diagnostics, pathology and staging, surgery, adjuvant therapy, radiotherapy, molecular targeted therapy, and immunotherapy for NSCLC, SCLC, and mesothelioma. Quality and value of care and perspectives on the future of lung cancer research and treatment have also been included in this concise review. © 2017 International Association for the Study of Lung Cancer
Keywords: gene mutation; overall survival; neutropenia; review; intensity modulated radiation therapy; bevacizumab; cisplatin; erlotinib; placebo; unspecified side effect; gemcitabine; adjuvant therapy; cancer adjuvant therapy; disease free survival; cancer staging; staging; biomarkers; carboplatin; ipilimumab; ticilimumab; unindexed drug; cancer immunotherapy; cancer prevention; computer assisted tomography; multiple cycle treatment; etoposide; lung lobectomy; radiotherapy; cancer screening; lung cancer; smoking cessation; smoking; pathology; cancer resistance; docetaxel; pneumonia; oncogene; lung adenocarcinoma; immunotherapy; screening; radiosurgery; gefitinib; brain metastasis; malignant mesothelioma; mesothelioma; surgery; targeted therapy; stereotactic body radiation therapy; pemetrexed; video assisted thoracoscopic surgery; radiation pneumonia; chemoradiotherapy; small cell lung cancer; hemoptysis; non small cell lung cancer; nsclc; whole brain radiotherapy; conformal radiotherapy; molecularly targeted therapy; sclc; crizotinib; vemurafenib; molecular diagnostics; dabrafenib; trametinib; afatinib; nivolumab; human; priority journal; ceritinib; pembrolizumab; alectinib; icotinib; durvalumab; robot assisted surgery; brigatinib; osimertinib; atezolizumab; liquid biopsy; value of therapy; early cancer diagnosis; avelumab; lorlatinib; vinorelbine tartrate; cannabis use; vaping
Journal Title: Journal of Thoracic Oncology
Volume: 12
Issue: 8
ISSN: 1556-0864
Publisher: Elsevier Inc.  
Date Published: 2017-08-01
Start Page: 1183
End Page: 1209
Language: English
DOI: 10.1016/j.jtho.2017.05.019
PROVIDER: scopus
PUBMED: 28579481
DOI/URL:

https://www.scopus.com/inward/record.uri?eid=2-s2.0-85030094918&doi=10.1016%2fj.jtho.2017.05.019&partnerID=40&md5=e9088218606a71ae2f0848db276016f9
Notes: Review -- Export Date: 4 December 2017 -- Source: Scopus
Altmetric
What is Altmetric?
Citation Impact
What is Dimensions Citation Badge?
BMJ Impact Analytics
MSK Authors
  1. Charles Rudin
    489 Rudin
Related MSK Work